Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions
Izalontamab Brengitecan Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions
Izalontamab Brengitecan Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Bristol Myers Squibb Announces ZENBEXUSTM in Combination with Daratumumab and Dexamethasone Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy in Adults and Pediatric Patients*
Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
QIMC Extends DDH-26-05 Drilling to Beyond 1,000 Metres and Launches In-Situ Hydrogen Characterization and Extraction Program at Bennett Hill as Seismic Further Corroborates Two Distinct Hydrogen Systems in Nova Scotia
CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary
